<div class="table-responsive">
    <table class="table table-striped table-hover">
        <thead>
            <tr>
                
                <th scope="col">
                    <a href="?cresstrial=1681&amp;modal=1&amp;valnames=primary_outcome&amp;order=created_at">Created at</a>
                </th>
                <th scope="col">Source</th>
                
                <th scope="col">Raw Value</th>
                <th scope="col">Validated value</th>
            </tr>
        </thead>
        <tbody>
            
            <tr class="histvalue-row" histvalueid="480536" class="table-">
                
                <td>Oct. 2, 2023, 10:07 a.m.</td>
                <td>usa</td>
                
                <td class="histvalue-container">
                    

        <p class="primary_outcome">
            Duration of Solicited AEs Occurring on the Day of Vaccination and the Following 7 Days After After Dose 1 and Dose 2;Geometric Mean Titers (GMTs) of SARS-CoV-2 Spike Protein RBD Antibodies on Day 29 and Day 43;GMTs of SARS-CoV-2 Neutralizing Antibodies on Day 29 and Day 43;Intensity of Solicited AEs Per US Food and Drug Administration (FDA) Toxicity Grading Scale Occurring on the Day of Vaccination and the Following 7 Days After Dose 1 and Dose 2;Intensity of Unsolicited AEs Per the Investigator&#x27;s Assessment Occurring on the Day of Vaccination and the Following 28 Days After Dose 1 and Dose 2;Number of Participants Who Experienced an Adverse Event of Special Interest (AESI) During the Trial;Number of Participants Who Experienced an Unsolicited AE Occurring on the Day of Vaccination and the Following 28 Days After Dose 1 and Dose 2;Number of Participants Who Experienced a Serious Adverse Event (SAE) During the Trial;Number of Participants Who Experienced a Solicited Adverse Event (AE) Occurring on the Day of Vaccination and the Following 7 Days After Dose 1 and Dose 2;Percentage of Participants Seroconverting for SARS-CoV-2 Neutralizing Antibodies on Day 29 and Day 43;Percentage of Participants Seroconverting for SARS-CoV-2 Spike Protein Receptor-Binding Domain (RBD) Antibodies on Day 29 and Day 43
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="primary_outcome validated">
            Duration of Solicited AEs Occurring on the Day of Vaccination and the Following 7 Days After After Dose 1 and Dose 2;Geometric Mean Titers (GMTs) of SARS-CoV-2 Spike Protein RBD Antibodies on Day 29 and Day 43;GMTs of SARS-CoV-2 Neutralizing Antibodies on Day 29 and Day 43;Intensity of Solicited AEs Per US Food and Drug Administration (FDA) Toxicity Grading Scale Occurring on the Day of Vaccination and the Following 7 Days After Dose 1 and Dose 2;Intensity of Unsolicited AEs Per the Investigator&#x27;s Assessment Occurring on the Day of Vaccination and the Following 28 Days After Dose 1 and Dose 2;Number of Participants Who Experienced an Adverse Event of Special Interest (AESI) During the Trial;Number of Participants Who Experienced an Unsolicited AE Occurring on the Day of Vaccination and the Following 28 Days After Dose 1 and Dose 2;Number of Participants Who Experienced a Serious Adverse Event (SAE) During the Trial;Number of Participants Who Experienced a Solicited Adverse Event (AE) Occurring on the Day of Vaccination and the Following 7 Days After Dose 1 and Dose 2;Percentage of Participants Seroconverting for SARS-CoV-2 Neutralizing Antibodies on Day 29 and Day 43;Percentage of Participants Seroconverting for SARS-CoV-2 Spike Protein Receptor-Binding Domain (RBD) Antibodies on Day 29 and Day 43
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="53787" class="table-">
                
                <td>Oct. 26, 2020, 11:31 p.m.</td>
                <td>usa</td>
                
                <td class="histvalue-container">
                    

        <p class="primary_outcome">
            Number of Participants with Unsolicited Adverse Events;Intensity of Solicited Systemic Adverse Events per the FDA Toxicity Grading Scale;Number of Participants with Solicited Systemic Adverse Events;Duration of Solicited Systemic Adverse Events;Number of Participants with Solicited Systemic Adverse Events Considered Related to Trial Vaccine;Intensity of Unsolicited Adverse Events per the FDA Toxicity Grading Scale;Number of Participants with Unsolicited Adverse Events Considered Related to Trial Vaccine;Number of Participants with One or More Serious Adverse Events (SAEs);Duration of Solicited Local Adverse Events;Intensity of Solicited Local Adverse Events per the FDA Toxicity Grading Scale;Number of Participants with One or More Serious Adverse Events (SAEs) Considered Related to Trial Vaccine;Number of Participants with Solicited Local Adverse Events;Number of Participants with One or More Adverse Events of Special Interest (AESIs);Number of Participants with One or More Adverse Events of Special Interest (AESIs) Considered Related to Trial Vaccine;Number of Participants Seroconverting for SARS-CoV-2 Spike Protein Antibodies;Number of Participants Seroconverting for SARS-CoV-2 Spike Protein Antibodies;Individual SARS-CoV-2 Spike Protein-Specific Antibody Levels in Serum;Individual SARS-CoV-2 Spike Protein-Specific Antibody Levels in Serum;Geometric Mean Titers (GMTs) of Serum SARS-CoV-2 Spike Protein Antibodies;Geometric Mean Titers (GMTs) of Serum SARS-CoV-2 Spike Protein Antibodies;Number of Participants Seroconverting for SARS-CoV-2 Neutralizing Antibodies;Number of Participants Seroconverting for SARS-CoV-2 Neutralizing Antibodies;Individual SARS-CoV-2 Neutralizing Antibody Levels in Serum;Individual SARS-CoV-2 Neutralizing Antibody Levels in Serum;Geometric Mean Titers (GMTs) of Serum SARS-CoV-2 Neutralizing Antibodies;Geometric Mean Titers (GMTs) of Serum SARS-CoV-2 Neutralizing Antibodies
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="primary_outcome validated">
            Number of Participants with Unsolicited Adverse Events;Intensity of Solicited Systemic Adverse Events per the FDA Toxicity Grading Scale;Number of Participants with Solicited Systemic Adverse Events;Duration of Solicited Systemic Adverse Events;Number of Participants with Solicited Systemic Adverse Events Considered Related to Trial Vaccine;Intensity of Unsolicited Adverse Events per the FDA Toxicity Grading Scale;Number of Participants with Unsolicited Adverse Events Considered Related to Trial Vaccine;Number of Participants with One or More Serious Adverse Events (SAEs);Duration of Solicited Local Adverse Events;Intensity of Solicited Local Adverse Events per the FDA Toxicity Grading Scale;Number of Participants with One or More Serious Adverse Events (SAEs) Considered Related to Trial Vaccine;Number of Participants with Solicited Local Adverse Events;Number of Participants with One or More Adverse Events of Special Interest (AESIs);Number of Participants with One or More Adverse Events of Special Interest (AESIs) Considered Related to Trial Vaccine;Number of Participants Seroconverting for SARS-CoV-2 Spike Protein Antibodies;Number of Participants Seroconverting for SARS-CoV-2 Spike Protein Antibodies;Individual SARS-CoV-2 Spike Protein-Specific Antibody Levels in Serum;Individual SARS-CoV-2 Spike Protein-Specific Antibody Levels in Serum;Geometric Mean Titers (GMTs) of Serum SARS-CoV-2 Spike Protein Antibodies;Geometric Mean Titers (GMTs) of Serum SARS-CoV-2 Spike Protein Antibodies;Number of Participants Seroconverting for SARS-CoV-2 Neutralizing Antibodies;Number of Participants Seroconverting for SARS-CoV-2 Neutralizing Antibodies;Individual SARS-CoV-2 Neutralizing Antibody Levels in Serum;Individual SARS-CoV-2 Neutralizing Antibody Levels in Serum;Geometric Mean Titers (GMTs) of Serum SARS-CoV-2 Neutralizing Antibodies;Geometric Mean Titers (GMTs) of Serum SARS-CoV-2 Neutralizing Antibodies
        </p>
        
    
                </td>
            </tr>
            
        </tbody>
    </table>
</div>
Created at	Source	Raw Value	Validated value
Oct. 2, 2023, 10:07 a.m.	usa	Duration of Solicited AEs Occurring on the Day of Vaccination and the Following 7 Days After After Dose 1 and Dose 2;Geometric Mean Titers (GMTs) of SARS-CoV-2 Spike Protein RBD Antibodies on Day 29 and Day 43;GMTs of SARS-CoV-2 Neutralizing Antibodies on Day 29 and Day 43;Intensity of Solicited AEs Per US Food and Drug Administration (FDA) Toxicity Grading Scale Occurring on the Day of Vaccination and the Following 7 Days After Dose 1 and Dose 2;Intensity of Unsolicited AEs Per the Investigator's Assessment Occurring on the Day of Vaccination and the Following 28 Days After Dose 1 and Dose 2;Number of Participants Who Experienced an Adverse Event of Special Interest (AESI) During the Trial;Number of Participants Who Experienced an Unsolicited AE Occurring on the Day of Vaccination and the Following 28 Days After Dose 1 and Dose 2;Number of Participants Who Experienced a Serious Adverse Event (SAE) During the Trial;Number of Participants Who Experienced a Solicited Adverse Event (AE) Occurring on the Day of Vaccination and the Following 7 Days After Dose 1 and Dose 2;Percentage of Participants Seroconverting for SARS-CoV-2 Neutralizing Antibodies on Day 29 and Day 43;Percentage of Participants Seroconverting for SARS-CoV-2 Spike Protein Receptor-Binding Domain (RBD) Antibodies on Day 29 and Day 43	Duration of Solicited AEs Occurring on the Day of Vaccination and the Following 7 Days After After Dose 1 and Dose 2;Geometric Mean Titers (GMTs) of SARS-CoV-2 Spike Protein RBD Antibodies on Day 29 and Day 43;GMTs of SARS-CoV-2 Neutralizing Antibodies on Day 29 and Day 43;Intensity of Solicited AEs Per US Food and Drug Administration (FDA) Toxicity Grading Scale Occurring on the Day of Vaccination and the Following 7 Days After Dose 1 and Dose 2;Intensity of Unsolicited AEs Per the Investigator's Assessment Occurring on the Day of Vaccination and the Following 28 Days After Dose 1 and Dose 2;Number of Participants Who Experienced an Adverse Event of Special Interest (AESI) During the Trial;Number of Participants Who Experienced an Unsolicited AE Occurring on the Day of Vaccination and the Following 28 Days After Dose 1 and Dose 2;Number of Participants Who Experienced a Serious Adverse Event (SAE) During the Trial;Number of Participants Who Experienced a Solicited Adverse Event (AE) Occurring on the Day of Vaccination and the Following 7 Days After Dose 1 and Dose 2;Percentage of Participants Seroconverting for SARS-CoV-2 Neutralizing Antibodies on Day 29 and Day 43;Percentage of Participants Seroconverting for SARS-CoV-2 Spike Protein Receptor-Binding Domain (RBD) Antibodies on Day 29 and Day 43
Oct. 26, 2020, 11:31 p.m.	usa	Number of Participants with Unsolicited Adverse Events;Intensity of Solicited Systemic Adverse Events per the FDA Toxicity Grading Scale;Number of Participants with Solicited Systemic Adverse Events;Duration of Solicited Systemic Adverse Events;Number of Participants with Solicited Systemic Adverse Events Considered Related to Trial Vaccine;Intensity of Unsolicited Adverse Events per the FDA Toxicity Grading Scale;Number of Participants with Unsolicited Adverse Events Considered Related to Trial Vaccine;Number of Participants with One or More Serious Adverse Events (SAEs);Duration of Solicited Local Adverse Events;Intensity of Solicited Local Adverse Events per the FDA Toxicity Grading Scale;Number of Participants with One or More Serious Adverse Events (SAEs) Considered Related to Trial Vaccine;Number of Participants with Solicited Local Adverse Events;Number of Participants with One or More Adverse Events of Special Interest (AESIs);Number of Participants with One or More Adverse Events of Special Interest (AESIs) Considered Related to Trial Vaccine;Number of Participants Seroconverting for SARS-CoV-2 Spike Protein Antibodies;Number of Participants Seroconverting for SARS-CoV-2 Spike Protein Antibodies;Individual SARS-CoV-2 Spike Protein-Specific Antibody Levels in Serum;Individual SARS-CoV-2 Spike Protein-Specific Antibody Levels in Serum;Geometric Mean Titers (GMTs) of Serum SARS-CoV-2 Spike Protein Antibodies;Geometric Mean Titers (GMTs) of Serum SARS-CoV-2 Spike Protein Antibodies;Number of Participants Seroconverting for SARS-CoV-2 Neutralizing Antibodies;Number of Participants Seroconverting for SARS-CoV-2 Neutralizing Antibodies;Individual SARS-CoV-2 Neutralizing Antibody Levels in Serum;Individual SARS-CoV-2 Neutralizing Antibody Levels in Serum;Geometric Mean Titers (GMTs) of Serum SARS-CoV-2 Neutralizing Antibodies;Geometric Mean Titers (GMTs) of Serum SARS-CoV-2 Neutralizing Antibodies	Number of Participants with Unsolicited Adverse Events;Intensity of Solicited Systemic Adverse Events per the FDA Toxicity Grading Scale;Number of Participants with Solicited Systemic Adverse Events;Duration of Solicited Systemic Adverse Events;Number of Participants with Solicited Systemic Adverse Events Considered Related to Trial Vaccine;Intensity of Unsolicited Adverse Events per the FDA Toxicity Grading Scale;Number of Participants with Unsolicited Adverse Events Considered Related to Trial Vaccine;Number of Participants with One or More Serious Adverse Events (SAEs);Duration of Solicited Local Adverse Events;Intensity of Solicited Local Adverse Events per the FDA Toxicity Grading Scale;Number of Participants with One or More Serious Adverse Events (SAEs) Considered Related to Trial Vaccine;Number of Participants with Solicited Local Adverse Events;Number of Participants with One or More Adverse Events of Special Interest (AESIs);Number of Participants with One or More Adverse Events of Special Interest (AESIs) Considered Related to Trial Vaccine;Number of Participants Seroconverting for SARS-CoV-2 Spike Protein Antibodies;Number of Participants Seroconverting for SARS-CoV-2 Spike Protein Antibodies;Individual SARS-CoV-2 Spike Protein-Specific Antibody Levels in Serum;Individual SARS-CoV-2 Spike Protein-Specific Antibody Levels in Serum;Geometric Mean Titers (GMTs) of Serum SARS-CoV-2 Spike Protein Antibodies;Geometric Mean Titers (GMTs) of Serum SARS-CoV-2 Spike Protein Antibodies;Number of Participants Seroconverting for SARS-CoV-2 Neutralizing Antibodies;Number of Participants Seroconverting for SARS-CoV-2 Neutralizing Antibodies;Individual SARS-CoV-2 Neutralizing Antibody Levels in Serum;Individual SARS-CoV-2 Neutralizing Antibody Levels in Serum;Geometric Mean Titers (GMTs) of Serum SARS-CoV-2 Neutralizing Antibodies;Geometric Mean Titers (GMTs) of Serum SARS-CoV-2 Neutralizing Antibodies